The HDAC Inhibitor FK228 Enhances Adenoviral Transgene Expression by a Transduction-Independent Mechanism but Does Not Increase Adenovirus Replication
2011

FK228 Enhances Adenoviral Transgene Expression

Sample size: 5 publication 10 minutes Evidence: moderate

Author Information

Author(s): Danielsson Angelika, Dzojic Helena, Rashkova Victoria, Cheng Wing-Shing, Essand Magnus

Primary Institution: Uppsala University

Hypothesis

The HDAC inhibitor FK228 enhances adenoviral transgene expression through a transduction-independent mechanism.

Conclusion

FK228 significantly enhances adenoviral transgene expression when administered after transduction, but it does not increase adenovirus replication.

Supporting Evidence

  • FK228 increased CD40L expression from 0.3% to 62% in TRAMP-C2 cells.
  • Transgene expression was highest when FK228 was added after transduction.
  • FK228 did not significantly upregulate CAR or other receptors needed for adenoviral infection.

Takeaway

FK228 is a drug that helps a virus deliver its genes better into cancer cells, but it doesn't make the virus multiply more.

Methodology

The study involved treating various cancer cell lines with FK228 and assessing transgene expression and cell viability through flow cytometry and MTS assays.

Potential Biases

Potential bias in the selection of cell lines and experimental conditions.

Limitations

The study primarily focused on in vitro models, which may not fully represent in vivo conditions.

Participant Demographics

Five healthy volunteers provided blood samples for PBMC isolation.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1371/journal.pone.0014700

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication